ストックスクリーナーアプリを入手
183.93
1.23%
2.24
アフターアワーズ：
183.93
前日終値:
$181.69
開ける：
$181
24時間の取引高:
435.47K
Relative Volume:
0.56
時価総額：
$11.73B
収益：
$13.84B
当期純損益:
$1.10B
株価収益率:
17.65
EPS:
10.4185
ネットキャッシュフロー:
$1.49B
1週間 パフォーマンス:
+4.03%
1か月 パフォーマンス:
+3.29%
6か月 パフォーマンス:
+22.56%
1年 パフォーマンス:
+41.91%
1日の値動き範囲:
$181.00
$184.53
1週間の範囲:
$176.38
$188.37
52週間の値動き範囲:
$101.00
$247.49
Davita Inc Stock (DVA) Company Profile
Compare DVA vs HCA, THC, EHC, FMS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DVA
Davita Inc
|
183.93 | 11.73B | 13.84B | 1.10B | 1.49B | 10.42 |
HCA
Hca Healthcare Inc
|
463.22 | 100.29B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
268.50 | 21.62B | 21.46B | 2.65B | 3.35B | 19.23 |
EHC
Encompass Health Corp
|
122.09 | 12.04B | 6.07B | 793.80M | 464.40M | 5.9914 |
FMS
Fresenius Medical Care Ag Adr
|
22.62 | 12.04B | 22.44B | 1.35B | 2.03B | 1.9002 |
Davita Inc Stock (DVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-08-07 | アップグレード | TD Cowen | Hold → Buy |
| 2026-05-06 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-03-06 | 開始されました | Barclays | Equal Weight |
| 2023-08-07 | アップグレード | UBS | Neutral → Buy |
| 2022-11-01 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-10-31 | ダウングレード | UBS | Buy → Neutral |
| 2022-08-19 | 再開されました | UBS | Buy |
| 2022-06-21 | 繰り返されました | BofA Securities | Underperform |
| 2021-09-10 | 開始されました | Cowen | Market Perform |
| 2021-08-12 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-03-26 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-01-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-01-24 | アップグレード | Goldman | Neutral → Buy |
| 2019-11-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-10-25 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2019-09-11 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2019-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-01-08 | アップグレード | UBS | Sell → Neutral |
| 2019-01-03 | 開始されました | Deutsche Bank | Buy |
| 2018-12-14 | 開始されました | Barclays | Overweight |
| 2018-11-28 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-11-16 | 開始されました | UBS | Sell |
| 2018-11-08 | ダウングレード | Raymond James | Strong Buy → Mkt Perform |
| 2018-09-13 | アップグレード | JP Morgan | Underweight → Neutral |
| 2018-01-04 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2017-12-12 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2017-12-11 | アップグレード | Citigroup | Neutral → Buy |
| 2017-12-07 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2017-11-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2017-10-09 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2017-06-26 | ダウングレード | Jefferies | Buy → Hold |
| 2016-12-13 | ダウングレード | Robert W. Baird | Outperform → Neutral |
すべてを表示
Davita Inc (DVA) 最新ニュース
DaVita earnings: what to look for from DVA - Yahoo Finance
DaVita settles ADA complaint with Lexington patient - WKYT
Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends? - Zacks Investment Research
Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends? - TradingView
DaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health Risks - PR Newswire
How Investors Are Reacting To DaVita (DVA) Kidney Week Research Push - Yahoo Finance
DaVita Inc. (DVA) Stock Forecasts - Yahoo! Finance Canada
DaVita Inc. stock outperforms competitors despite losses on the day - MarketWatch
DaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know - Zacks Investment Research
DaVita Inc. Estimates – NYSE:DVA - TradingView
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally? - Zacks Investment Research
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally? - TradingView
DaVita Earnings Preview: What to Expect - Barchart.com
DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance
HHS Kidney Care Plan Raises Concerns for DaVita (DVA) Amid Positive Analyst Outlook - GuruFocus
DaVita Responds to HHS Kidney Care National Plan, Reaffirms Commitment to Innovation, Access and Patient Choice - PR Newswire
DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance
A Look at DaVita Inc (DVA) After 6.2% Decline -- GF Value $198.0 - GuruFocus
Why DaVita (DVA) Stock Is Nosediving - Yahoo Finance
Why DaVita (DVA) Stock Is Nosediving - TradingView
DaVita falls 6% amid proposed kidney care plan (DVA:NYSE) - Seeking Alpha
DaVita Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
HHS Launches Kidney Care National Plan, Impacting DaVita Inc (DV - GuruFocus
DaVita (DVA) Shares Slip Amid Trump Administration Dialysis Mark - GuruFocus
DaVita, Fresenius drop as HHS seeks dialysis market reforms (DVA:NYSE) - Seeking Alpha
DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call - The Napa Valley Register
DaVita $15 Million Data Breach Class Action Settlement - Claim Depot
DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call - DaVita Newsroom
DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know - Zacks Investment Research
DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know - Yahoo Finance
A Look at DaVita Inc (DVA) After 4.7% Gain -- GF Value $197.72 v - GuruFocus
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
Davita Brings New Clinical Research to Asn Kidney Week, Advancing Evidence for the Next Era of Kidney Care - www.marketscreener.com
Why patients miss dialysis is one focus of seven studies DaVita will present. - Stock Titan
DaVita Inc. (DVA) Stock forecasts - Yahoo Finance UK
Davita Inc Share PriceDVA, RNS News, Articles, Quotes, & Charts (NYSE:DVA) - Proactive financial news
DaVita Inc. (DVA) Stock Forecasts - Yahoo! Finance Canada
DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
DaVita Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Why DaVita HealthCare (DVA) Outpaced the Stock Market Today - Zacks Investment Research
DaVita rated Buy with 22% upside, driven by agg... - Pluang
DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again (NYSE:DVA) - Seeking Alpha
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - Zacks Investment Research
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - TradingView
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - Yahoo Finance
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - TradingView
DaVita Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
DaVita Inc Bills, 2006 - OpenSecrets
Davita Inc (DVA) 財務データ
収益
当期純利益
現金流量
EPS
Davita Inc (DVA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Javier Rodgriguez | Officer |
Jun 16 '26 |
Proposed Sale |
209.28 |
39,407 |
8,247,016 |
0 |
| Rodriguez Javier | Chief Executive Officer |
Jun 16 '26 |
Sale |
209.28 |
39,407 |
8,247,018 |
840,408 |
| Kathleen Waters | Officer |
Jun 15 '26 |
Proposed Sale |
207.84 |
8,950 |
1,860,202 |
0 |
| Javier Rodriguez | Officer |
Jun 15 '26 |
Proposed Sale |
209.50 |
30,000 |
6,285,102 |
0 |
| Waters Kathleen Alyce | Officer |
Jun 15 '26 |
Proposed Sale |
207.93 |
6,455 |
1,342,188 |
0 |
| Waters Kathleen Alyce | Chief Legal & Pub. Affairs Off |
Jun 15 '26 |
Sale |
208.40 |
15,405 |
3,210,377 |
109,194 |
| Rodriguez Javier | Chief Executive Officer |
Jun 15 '26 |
Sale |
209.50 |
30,000 |
6,285,090 |
879,815 |
| HEARTY JAMES O | Chief Compliance Officer |
May 15 '26 |
Sale |
193.98 |
15,000 |
2,909,745 |
22,389 |
| James Hearty | Officer |
May 15 '26 |
Proposed Sale |
193.93 |
15,000 |
2,908,950 |
0 |
| HEARTY JAMES O | Chief Compliance Officer |
May 14 '26 |
Option Exercise |
110.63 |
5,784 |
639,884 |
41,737 |
0.53%
2.90%
大文字化:
|
ボリューム (24 時間):